Apyx Medical Corporation (NASDAQ:APYX) investors will be delighted, with the company turning in some strong numbers with its latest results. The results overall were pretty good, with revenues of US$12m exceeding expectations and statutory losses coming in at justUS$0.05 per share, some 55% below what the analysts had forecast. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Apyx Medical after the latest results.

Taking into account the latest results, the consensus forecast from Apyx Medical's four analysts is for revenues of US$59.6m in 2026. This reflects a credible 6.5% improvement in revenue compared to the last 12 months. Losses are forecast to balloon 28% to US$0.28 per share. Before this latest report, the consensus had been expecting revenues of US$57.8m and US$0.36 per share in losses. So it seems there's been a definite increase in optimism about Apyx Medical's future following the latest consensus numbers, with a considerable decrease in the loss per share forecasts in particular.

The consensus price target rose 8.3% to US$6.50, with the analysts encouraged by the higher revenue and lower forecast losses for next year. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. The most optimistic Apyx Medical analyst has a price target of US$8.00 per share, while the most pessimistic values it at US$6.00. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. The analysts are definitely expecting Apyx Medical's growth to accelerate, with the forecast 8.8% annualised growth to the end of 2026 ranking favourably alongside historical growth of 4.2% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 7.9% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Apyx Medical is expected to grow at about the same rate as the wider industry.

The Bottom Line

The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. There was also an upgrade to revenue estimates, although as we saw earlier, forecast growth is only expected to be about the same as the wider industry. We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Apyx Medical analysts - going out to 2028, and you can see them free on our platform here.

You still need to take note of risks, for example - Apyx Medical has 2 warning signs we think you should be aware of.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.